Navigation Links
Volcano Reports Second Quarter Results; Medical Segment Revenues Increase More Than 13 Percent On A Constant Currency Basis

SAN DIEGO, Aug. 5, 2013 /PRNewswire/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today reported results for the second quarter and first six months of 2013.

For the quarter ended June 30, 2013, Volcano reported revenues of $101.3 million, an increase of six percent on a reported basis versus the same period a year ago and 12 percent on a constant currency basis after adjusting for a negative impact of approximately $5.5 million from foreign currency. Medical segment revenues increased more than seven percent and more than 13 percent on a reported and constant currency basis, respectively.

The company reported a net loss on a GAAP basis of $2.4 million, or $0.04 per share, in the second quarter of 2013, versus net income of $3.3 million, or $0.06 per diluted share, in the same period a year ago. The results for the quarter include net interest expense of $6.6 million versus $1.7 million a year ago, reflecting the company's convertible debt offering completed in the fourth quarter of 2012. The company also recorded a gain on a strategic investment of $2.2 million and acquisition-related charges of $911,000 in the second quarter of 2013.

Excluding acquisition related items, amortization of intangibles and non-cash interest expense on convertible notes, net of tax, the company reported non-GAAP earnings per diluted share of $0.03.

For the first six months of 2013, Volcano reported revenues of $194.6 million versus $185.7 million a year ago. This represents an increase of five percent on a reported basis versus the same period a year ago and 10 percent on a constant currency basis after adjusting for a $9.7 million negative effect from foreign currency. Medical segment revenues increased six percent and 11 percent on a reported and constant currency basis, respectively. The company reported a net loss on a GAAP basis of $5.5 million, or $0.10 per share, for the first six months of 2013, versus net income on a GAAP basis of $3.6 million, or $0.06 per diluted share, in the same period a year ago. The results for the first six months of 2013 included net interest expense of $13.2 million versus $3.1 million a year ago. In addition, the company recorded an expense of $2.5 million related to acquisitions and a gain of $4.1 million related to a strategic investment. The company also recorded an exchange rate loss of $1.1 million in the first six months of 2013 versus $101,000 in the same period a year ago. 

Excluding acquisition related items, amortization of intangibles and non-cash interest expenses on convertible notes, net of tax, the company reported non-GAAP earnings per diluted share of $0.06.

"Volcano experienced a solid increase in our FFR (Fractional Flow Reserve) disposables business, including 25 and 29 percent on a reported and constant currency basis, respectively, highlighted by growth in Europe and Japan. In addition, our IVUS (Intravascular Imaging) revenues met our expectations, driven by a greater than 25 percent increase in peripheral imaging revenues versus the second quarter a year ago," said Scott Huennekens, president and chief executive officer.

"We continue to achieve market share gains and are setting the stage for future growth with initiatives such as our iFR® (Instant Wave-Free Ratio) FFR technology. The launch of iFR in Europe is going very well and we just initiated our market launch in Japan. The outcomes to date from the study that will support our U.S. regulatory submissions have been encouraging. We also recently received FDA clearance for our new Verrata™ FFR wire, which will represent our fifth new guide wire in five years, and plan to initiate a full market release for Verrata later this year," he added.


The company reconfirmed its prior guidance for 2013. Based on current foreign currency exchange rates, it expects revenues on a reported basis of $394.0-$400.0 million, with revenues on a constant currency basis in the range of $418.0-$424.0 million.

The company expects gross margins on a reported basis will be in the range of 64.5-65.0 percent and that operating expenses will be 65.0-66.0 percent of revenues. On a reported basis, the company expects a GAAP net loss of $0.26-$0.28 per share. This assumes an expected tax benefit of approximately $0.20 per share, based on an annual tax rate of 38.5 percent, combined with a $1 million R&D tax credit from 2012 that was recorded in the first quarter of 2013. On a reported basis, the company expects non-GAAP net income of $0.03-$0.05 per diluted share. Non-GAAP results exclude acquisition-related expenses, amortization of intangibles and non-cash interest expense, and assume an effective tax rate of 38.0 percent for the GAAP to non-GAAP adjustments. The company expects weighted average basis shares in 2013 will be approximately 54.4 million shares and approximately 56.2 million shares on a diluted basis.

Conference Call Information

The company will hold a conference call at 2 p.m., Pacific Daylight Time, (5 p.m., Eastern Daylight Time) today. The teleconference can be accessed by calling (631) 291-4555, passcode 11845995, or via the company's website at Please dial in or access the webcast 10-15 minutes prior to the beginning of the call. A replay of the conference call will be available through August 12, at (404) 537-3406 passcode 11845995, and via the company's website at

About Volcano

Volcano Corporation (Nasdaq: VOLC) is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using light and sound as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at

Note Regarding the Use of Non-GAAP Financial Measures

The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The company uses non-GAAP financial measures for financial and operational decision making and as a means to compare period-to-period results. The company believes that they provide useful information about operating results, enhance the overall understanding of operating results and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.

Constant Currency Basis Revenue Changes: Volcano reports changes in revenues on a constant currency basis, which is a non-GAAP financial measure. Volcano believes that investors' understanding of the company's short-term and long-term financial results is enhanced by taking into consideration the impact of foreign currency translation on revenue. In addition, Volcano's management uses results of operations before currency translation to evaluate the operational performance of Volcano and as a basis for strategic planning.

Volcano reports its expectations of earnings per share performance excluding certain expenses described below; for additional details please see the "Reconciliation of GAAP to non-GAAP EPS Guidance" table in this press release. This accompanying table has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.

Exclusion of Acquisition-Related Expenses: Volcano excludes acquisition-related expenses because it does not consider these acquisition-related costs and adjustments to be related to the  continuing organic operations of the acquired businesses and are generally not relevant to assessing or estimating the long-term performance of the acquired assets. In addition, the size, complexity and/or volume of past acquisitions, which often drive the magnitude of acquisition-related costs, may not be indicative of the size, complexity and/or volume of future acquisitions.

Exclusion of Amortization of Intangibles: Volcano excludes amortization of intangibles because is it a non-cash expense relating primarily to acquisitions. At the time of an acquisition, the intangible assets of the acquired company, such as technology and supplier agreements, are valued and amortized over their estimated lives. Volcano believes that since intangible assets represent efforts of the acquired company to build value prior to acquisition, Volcano management eliminates the impact of the amortization when evaluating its current operating performance.

Exclusion of Non-Cash Interest Expense: In addition to disclosing the financial statement impact of the authoritative guidance for convertible debt accounting, Volcano management believes that excluding the impact of this authoritative guidance because it is non-cash in nature, may provide meaningful supplemental information regarding elements of the company's borrowing costs in order to properly understand its operational performance and liquidity, and facilitates comparisons to competitors' results.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding Volcano's expected revenues, revenue growth and financial results for the year ended December 31, 2013, its growth and other strategies and ability to execute on those strategies, competitive positioning, target markets, development of its base business and pipeline, benefits from recent acquisitions and benefits from its products and technologies. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that may cause Volcano's actual results to differ materially and adversely from statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the risk that Volcano's revenue, expense, earnings, earnings per share, margin or other projections may turn out to be inaccurate or Volcano may encounter unanticipated difficulty in achieving these projections; global and regional macroeconomic conditions, generally, and in the medical device and telecom industries specifically; current exchange rate fluctuations; the effect of competitive factors and the company's reaction to those factors; purchasing decisions with respect to the company's products; the pace and extent of market adoption of the company's products and technologies; uncertainty in the process of obtaining regulatory approval or clearances for Volcano's products or devices; the success of Volcano's growth and other strategies, including the integration of recently-acquired businesses and our ability to integrate businesses from future acquisitions; risks associated with Volcano's international operations; timing and achievement of product development milestones; outcome of ongoing or future litigation; investigations and claims; the impact and benefits of market development and the related size of Volcano's addressable markets; our ability to protect our intellectual property; dependence upon third parties; unexpected new data, safety and technical issues; market conditions and other risks inherent to medical and/or telecom device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our 10-K for the year ended December 31, 2012, our 10-Q for the quarter ended March 31, 2013, and other filings made with the Securities and Exchange Commission, which should be read in conjunction with these financial results. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


  VOLCANO CORPORATION  CONDENSED CONSOLIDATED BALANCE SHEETS  (in thousands)  (unaudited)  June 30,  December 31, 20132012 Assets  Current assets:  Cash and cash equivalents 

$   301,760$
330,635 Short-term available-for-sale investments136,090140,960 Accounts receivable, net 

77,69276,348 Inventories 

57,76752,811 Prepaid expenses and other current assets 

31,55821,773Total current assets 

604,867622,527 Restricted cash 

702711 Long-term available-for-sale investments 

63,08444,385 Property and equipment, net 

111,676104,385 Intangible assets, net 

50,74350,657 Goodwill 

51,37751,577 Other non-current assets 

27,07728,102 Total Assets $   909,526$
902,344 Liabilities and Stockholders' Equity  Current liabilities:  Accounts payable 

,284 Accrued compensation 

24,73223,227 Accrued expenses and other current liabilities 

18,45723,476 Deferred revenues 

9,6629,789 Contingent consideration 

2,9002,908 Current maturities of long-term debt 

6153Total current liabilities 

67,29875,737 Convertible senior notes 

391,493382,300 Other long-term debt 

1,1921,119 Deferred revenues 

4,6704,661 Contingent consideration, non-current portion 

28,78727,323 Other non-current liabilities 

2,7292,859Total liabilities 

496,169493,999 Stockholders' equity 

413,357408,345 Total Liabilities and Stockholders' Equity $   909,526$

 VOLCANO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)Three Months Ended
June 30,Six Months Ended
June 30,2013201220132012Revenues$




185,733Cost of revenues, excluding amortization of intangibles36,03931,97669,16661,549Gross profit65,30563,397125,409124,184Operating expenses:Selling, general and administrative45,73441,99189,56386,336Research and development17,95413,87933,60527,528Amortization of intangibles8208881,6541,760Acquisition-related items911-2,489-Total operating expenses65,41956,758127,311115,624Operating (loss) income(114)6,639(1,902)8,560Interest income305203643433Interest expense(6,607)(1,677)(13,152)(3,149)Exchange rate (loss) gain(301)74(1,079)(101)Other, net2,279884,177(8)(Loss) income before income tax(4,438)5,327(11,313)5,735Income tax (benefit) expense(2,050)2,028(5,764)2,165Net (loss) income$




3,570Net (loss) income per share:Basic$








0.06Shares used in calculating net (loss) income per share:Basic54,57453,36254,38953,146Diluted54,57455,20754,38955,136 

June 30,20132012Operating activitiesNet (loss) income



3,570Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Depreciation and amortization12,22311,595Amortization (accretion) of investment premium (discount), net1,3781,313Accretion of debt discount on convertible senior notes and other long-term liabilities9,3412,449Accretion of contingent consideration1,656-Non-cash stock-based compensation expense7,8477,492Gain on sale of other long-term investment(1,925)-Effect of exchange rate changes and others9,1392,795Changes in operating assets and liabilities(32,583)(1,159)Net cash provided by operating activities1,52728,055Investing activitiesPurchase of short-term and long-term available-for-sale investments(154,887)(177,740)Sale or maturity of short-term and long-term available-for-sale securities139,494115,867Capital expenditures(18,490)(27,652)Cash paid for other intangible assets and investments(1,692)(1,910)Proceeds from sale of long-term investments3,426-Proceeds from foreign currency exchange contracts-501Payment for foreign currency exchange contracts-(15)Net cash used in investing activities(32,149)(90,949)Financing activitiesRepayment of capital lease liability(15)(44)Proceeds from sale of common stock under employee stock purchase plan1,7131,898Proceeds from exercise of common stock options1,1855,432Net cash provided by financing activities2,8837,286Effect of exchange rate changes on cash and cash equivalents(1,136)(306)Net decrease in cash and cash equivalents(28,875)(55,914)Cash and cash equivalents, beginning of period330,635107,016Cash and cash equivalents, end of period




 VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Three Months Ended
June 30,Percentage Change
2012 to 2013Currency Impact Constant Currency Percentage Change20132012DollarPercentageMedical segment:Consoles:United States

.9$   6.65





2.71.751-546Rest of world

1.81.9(4)--(4)Total Consoles

$   11.5$ 10.78$
-17IVUS single-procedure disposables:United States

$   20.7$ 20.51





6.45.516-115Rest of world

2.21.638--38Total IVUS single-procedure disposables

$   49.9$ 51.6(3)$ (4.3)(8)5FFR single-procedure disposables:United States

$   15.1$ 12.619





8.06.425-124Rest of world

1.20.763--63Total FFR single-procedure disposables

$   28.7$ 22.925$ (0.9)(4)29Other

8.9$   6.931

%$ (0.3)(5)


%Sub-total medical segment

$   99.0$ 92.17$ (5.5)(6)13Industrial segment

2.3$   3.3(28)$

$ 101.3$ 95.46$ (5.5)(6)12 

 VOLCANO CORPORATIONREVENUE SUMMARY(in millions)(unaudited)Six Months Ended
June 30,Percentage Change
2012 to 2013Currency Impact Constant Currency Percentage Change20132012DollarPercentageMedical segment:Consoles:United States

$   11.7$   11.8(1)





4.22.850-347Rest of world

3.52.9230.1221Total Consoles

$   20.5$   18.99$(0.1)-9IVUS single-procedure disposables:United States

$   40.0$   40.1-





12.210.912-111Rest of world

4.43.429--29Total IVUS single-procedure disposables

$   97.8$105.1(7)$(7.5)(7)-FFR single-procedure disposables:United States

$   28.7$   24.318





15.912.6260.1125Rest of world

2.01.265--65Total FFR single-procedure disposables

$   55.5$   43.129$(1.5)(3)32Other

$   16.9$   13.425



%Sub-total medical segment

$190.7$180.56$(9.7)(5)11Industrial segment



 VOLCANO CORPORATIONRECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS(in thousands, except per share data)(Unaudited)Three Months Ended June 30, 2013Pre-tax AdjustmentsNet of Tax (1)Earnings Per ShareGAAP net loss $ (2,388)$ (0.04)Acquisition related items

9115650.01Amortization of intangibles

8205080.01Non-cash interest expense on convertible notes

4,6962,9120.05Non-GAAP net income

$ 6,427$ 1,597$ 0.03Weighted average shares outstanding—diluted 54,574Six Months Ended June 30, 2013Pre-tax AdjustmentsNet of Tax (1)Earnings Per ShareGAAP net loss $ (5,549)$ (0.10)Acquisition related items

2,4891,5430.03Amortization of intangibles

1,6541,0250.02Non-cash interest expense on convertible notes

9,2685,7460.11Non-GAAP net income income

$ 13,411$ 2,765$ 0.06Weighted average shares outstanding—diluted 54,389(1) Effective tax rate of 38% applied to non-GAAP adjustments 

 VOLCANO CORPORATIONRECONCILIATION OF GAAP TO NON-GAAP EPS GUIDANCE(in thousands, except per share data)(Unaudited)2013Guidance RangeFromTo GAAP net loss per share—basic 

$  (0.28)$  (0.26) GAAP net loss per share—diluted 

$  (0.28)$  (0.26) Acquisition related items 

.06 Amortization of intangibles 

.04 Non-cash interest expense 

.21 Non-GAAP net income per share—diluted 

.05 Weighted average shares outstanding—basic 

54,40054,400 Weighted average shares outstanding—diluted 

56,20056,200Note: Effective tax rate of 38% applied to non-GAAP adjustments 


SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance ... greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to ... and deadly chromosome abnormality. , After struggling since birth with several health challenges, ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):